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Introduction: The COPD airway is infiltrated with CD8+ T cells, which has led to a virus
being implicated in its pathogenesis. Some investigators have suggested a role for the
persistence of the adenovirus E1A in bronchial epithelial cells. We examined respiratory
tract specimens from COPD patients for the presence of E1A DNA and mRNA using real-time
PCR.
Methods: Nucleic acid extraction was performed on sputum specimens from patients with
COPD. Copy numbers for GAPDH, and adenovirus 5 E1A DNA and mRNA were determined
using a quantitative real-time PCR assay. All samples were screened for the adenovirus
hexon gene using nested PCR.
Results: One hundred and seventy-one patients, 80 male, aged 68.979.8 years with COPD
were recruited. One hundred and thirty-six were seen during an exacerbation when
admitted to hospital, 33 of whom were reviewed when clinically stable along with an
additional 35 stable COPD patients. Ten patients in the exacerbation group were positive
for the adenovirus hexon gene (7%), as were four in the stable group (6%). Only two
patients in the exacerbation group were positive for adenovirus 5 E1A. Only one patient in
the stable COPD group had detectable E1A DNA/mRNA and also tested positive for the
adenovirus hexon gene.
Conclusion: Adenovirus is detected in similar frequencies in exacerbated and stable COPD
patients. Adenovirus E1A DNA is infrequently detected in respiratory secretions from
patients with COPD. Our data suggest that the persistence of adenovirus 5 E1A in lung cells
of sputum samples in patients with COPD occurs infrequently.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Adenovirus in COPD 2085Introduction stable. A further 35 stable COPD patients were recruitedFigure 1 Study design.COPD is a progressive disease which progresses over the
lifetime of the patient.1 It is currently the sixth commonest
cause of death, and it is due to rise to the third commonest
cause by 2020.2 Only 20% of smokers develop airflow
obstruction.1,3 It has thus been postulated that other factors
including latent adenoviral infection may amplify the
inflammatory response to cigarette smoke resulting in the
COPD phenotype.4 Previous work investigating the role of
latent adenoviral infection has focused on group C adeno-
virus, adenovirus 5 early expressed antigen (E1A).5 Group C
adenovirus is endemic and children are often infected
resulting in latent infection.4 The development of COPD is
associated with poverty,6 and infections are more likely to
develop in children of lower socioeconomic status.7
Adenoviruses are nonenveloped, double-stranded DNA
viruses, and over 50 serotypes have been isolated and
characterized into 6 subgroups (A–F). Types 4 (group E), 7
(group B) and 1, 2 and 5 (group C) viruses most frequently
cause respiratory disease in adults. The incubation period is
5–8 days. Infections usually occur within the first year of life
with most children having serological evidence of infection
by 6 months.8 It is recognized as a common respiratory
pathogen in children but is infrequently detected in adult
populations with COPD with detection in 0.5–1.5% of
exacerbations.9,10 Detection of adenovirus in bronchoalveo-
lar lavage fluid (BALF) has been linked to severe lower
respiratory tract infection in immunocompromised indivi-
duals.11 Adenovirus has also been linked to more sympto-
matic episodes and even near fatal asthma.12 Mitchell
et al.13 showed that adenoviral infection is significantly
under reported when using non-molecular methods for
detection. These finding suggest that adenoviral infection
may be more common in immunocompromised individuals.
Also asymptomatic illness can be followed by latent viral
infection.
Exacerbations of COPD account for significant morbidity
and mortality.14,15 Bacteria are isolated from sputum in
40–60% of acute COPD exacerbations.16–18 Some COPD
patients suffer from frequent exacerbations. This subgroup
have a worse health status and a more rapid decline in
FEV1.
19,20 Studies using serology and viral culture identified
respiratory viruses in 30% of patients during acute exacer-
bations of COPD.21 Recently with the development of more
sensitive molecular tests the role of viruses in COPD has
been better defined.9,10,22
As detailed above latent adenoviral infection is proposed
as a causative factor in the pathogenesis of COPD. We
wished to determine the prevalence of acute (adenovirus
hexon gene) and latent adenoviral infection (E1A gene) in
COPD exacerbations and also to determine if there was
latency of this virus by testing stable COPD patients.
Methods
Subjects
One hundred and thirty-six patients hospitalized with COPD
were recruited within 24 h of presentation. Thirty-three of
these patients were subsequently reviewed when clinically(Fig. 1). All recruitment was carried out over a 2-year
period. Stability was defined as no change in respiratory
symptoms in the previous 8 weeks. Spirometry and
reversibility (improvement in FEV1 following nebulised beta
agonist) were performed. The best of 3 reproducible
readings was taken. The test was performed with a
Vitalograph spirometer (Vitalograph, Buckingham, England).
Reversibility was performed after nebulised beta agonist
(salbutamol 2.5mg). Exacerbated and stable COPD subjects
were included in this study in order to determine if E1A
detection was related to acute adenoviral infection whilst
also to find if patients remained E1A positive or negative by
sampling at two time points. This study was approved by the
Queen’s University Belfast ethics committee and all patients
gave written consent.Inclusion/exclusion criteria and definitions
COPD diagnosis and assessment of severity was classified
according to the GOLD criteria.23 Exacerbation of COPD
were defined using inclusion criteria as detailed above with
symptoms of increased dyspnoea, increased sputum puru-
lence or increased sputum production.24 Stable COPD was
defined using inclusion criteria as detailed above without
any symptoms of exacerbation or changes in treatment
within the last 8 weeks. Those patients with a history of
bronchiectasis, neoplastic process or other serious conco-
mitant disease were excluded. Patients who had significant
improvement following bronchodilator therapy (+200ml in
FEV1/+15%) were excluded.
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Figure 2 Log dilutions of E1A cloned material run on a
Lightcycler. Notation: This illustrates log dilutions of Adenovirus
E1A DNA cloned target (106–1013) which were run on the
Lightcycler to perform an end point titration. Second round
samples were PCR positive out to 1011 dilution.
T.E. McManus et al.2086Power calculation
This study was linked to a COPD exacerbation study
examining the role of acute respiratory viral infection in
exacerbations of COPD (unpublished data). Assuming an
acute respiratory virus detection rate of 30% amongst COPD
patients during exacerbations and 10% detection when
stable a power calculation was performed using EpiInfoTM
version 6. This calculation was performed in order to
determine group size required to detect a significant
difference in the frequency of respiratory virus infection
between exacerbated and stable COPD groups. Using a
confidence value of 95% with a power of 80% and a 2:1 ratio
of group sizes, 111 patients with COPD exacerbations and 56
stable COPD subjects were required to detect a significant
difference in the incidence of respiratory virus infection
between groups.
Samples
Sputum sampling
Sputum samples were obtained either by spontaneous
production or following nebulised hypertonic saline. Briefly,
4ml of 3% saline was nebulised via an air driven nebuliser
(Micro Mists small volume nebuliser, Hudson Respiratory
Care Inc., Leicestershire, UK). Every 5min spirometry was
repeated to measure FEV1, and nebulization continued if
FEV1 had not fallen by more than 20%. This was continued up
to 20min. All sputum expectorated was collected.
Sputum processing
All samples were processed within 2 h. Specimens were
mixed with 4 volumes 0.1% dithiothreitol (Sigma, Poole, UK)
and shaken in an orbital Incubator (Gallenkamp, Loughbor-
ough, UK) for 15min at 37 1C followed by the addition of 4
volumes phosphate buffered saline and shaken for a further
5min. The resulting suspension was then filtered through
50 mm Nylon Gauze (Lockertex, Warrington, UK) and spun
down at 1000g for 10min. After removing the supernatant
the cell pellet was resuspended in Lysis Buffer (Qiagen,
Crawley, UK). Total nucleic acid extraction was performed
on 200 ml of sputum sample suspended in Lysis Buffer
(QIAamp DNA Blood Mini Kit).
Polymerase chain reaction
Following nucleic acid extraction, 2 ml of each specimen was
combined with 8 ml of mastermix containing primers specific
to adenovirus 5 E1A DNA or mRNA. All primers and probes
are shown in Table S1. First round mastermix was prepared
using the Access RT PCR System (Promega, Southampton,
UK). PCR was performed on a Peltier thermal cycler (MJ
Research, Essex, UK) for 20 cycles and 0.2 ml of the first
round product was then used in combination with 9.8 ml of
mastermix containing primers and a TaqMans (Qiagen,
Crawley, UK) probe (labeled with FAM and TAMRA dyes)
internal to the first round primers. Real-time PCR (30 cycles)
was carried out using a Roche LightCycler (Roche Diagnostics
Corporation, Mannheim, Germany) with log dilutions of the
cloned target sequence being used as calibrators thus
enabling quantitation of copy numbers in unknown speci-mens (Fig. 2). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was also employed, using identical methods to
those above, as a housekeeping gene, and using a published
primer and probe set with a set of external nested
primers.25
The E1A DNA primers used in these experiments were
designed internal to those described in previous E1A work.26
Nested PCR primers and a probe were also designed for
adenovirus E1A mRNA using published sequences and
DNAStar primer design software (DNAStar, Madison, USA).
The E1A DNA, E1A mRNA and GAPDH LightCycler assays of
the cloned target sequences had detection limits of 5, 7 and
6 copies per reaction, respectively, added in a 2ml volume
(in contrast to the LightCyler PCR reaction volume which
was 10 ml). Coefficient of variation for these assays was
calculated at between 5% and 13%. A positive result was
recorded if a copy number greater than zero was obtained
following completion of real-time PCR.
All specimens were tested for the adenovirus hexon gene
(capsular protein) using a nested PCR approach and
published primers,27 the technique for this assay has
previously been described.13 The hexon PCR primers are
designed to detect up to 18 subtypes of adenovirus,
including the respiratory subtypes B–E. Results were
obtained using gel electrophoresis. A positive result was
recorded if there was a band seen corresponding to the
correct size for a first or second round product (Fig. 3).
Further details of all of the above assays are listed in
Appendix A1.
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Figure 3 Testing clinical specimens for adenovirus hexon
gene. Notation: Eight clinical specimens tested for adenovirus
using nested primers. Molecular weight markers flank the PCR
products. Top and bottom products represent first and second
round results, respectively. Positive control is in lane 8. Specific
first and second round product sizes of 301 and 185 base pairs
are seen.
Adenovirus in COPD 2087Cell culture inoculation
We infected primary bronchial epithelial cells with adeno-
virus 5 as positive test specimens. Primary cultures of
bronchial epithelial cells obtained by non-bronchoscopic
brush method were cultured as previously described.28
Nucleic acid extraction and PCR techniques were identical
to those detailed above. This study was approved by the
Queen’s University Belfast ethics committee and written
consent obtained. Further details are listed in Appendix A1.Results
COPD patients
One hundred and seventy-one patients, 80 male, aged
68.979.8 years (mean7SD) with COPD, FEV1 0.9070.52 l,
41% predicted, were recruited. Ninety-two percent of
patients had smoked 46.1736.3 pack years (Table 1). One
hundred and thirty-six were seen during an exacerbation
when admitted to hospital, 33 of whom were reviewed when
clinically stable along with an additional 35 stable COPD
patients. Real time PCR analysis for GAPDH mRNA showed a
median (IQR) copy number of 2295 (365–12,101) copies per
epithelial cell in the specimens(Table 2). Ten exacerbated
patients were positive for the adenovirus hexon gene
(capsular protein). Only two patients in the exacerbation
group were positive for adenovirus 5 E1A DNA with a copy
number of 3.4 105 and 7.0 104 copies per epithelial cell.
Nine of the patients testing positive for the adenovirus
hexon gene were negative for E1A, the remaining one
patient who had tested positive for both the adenovirus
hexon gene and E1A was negative on repeat testing for E1A
(DNA and mRNA)and the adenovirus hexon gene when
retested 3 months later. Only one patient in the stable
COPD group had detectable E1A DNA/mRNA 3003/1257
copies per epithelial cell, this patient initially tested
negative for adenovirus, E1A DNA and E1A mRNA. It was
also noted that this patient plus one other patient in this
stable group tested positive for the adenovirus hexon gene.
Epithelial cell cultures (positive controls)
Eleven epithelial cell cultures were inoculated with adeno-
virus 5. In each case higher copy numbers of adenovirus
were detected following infection than were present in the
inoculating dose. Cytopathic effect was seen in each case.
GAPDH was detectable in all specimens; median (IQR)
2.4 107 (1.6 106–5.0 107) copies per reaction. All
samples tested positive for the adenovirus hexon gene.
Adenovirus 5 E1A DNA was detectable in all samples;
1.7 1012 (8.3 1010–3.8 1012) copies per reaction, or
when adjusted for GAPDH; 4.2 104 (1380–2.6 105) copies
per reaction. Adenovirus E1A mRNA was also detectable
in all samples; 8.0 1010 (2.7 1010–1.2 1012) copies
per reaction, or when adjusted for GAPDH; 22773
(446–6.2 104) copies per reaction. Adenovirus hexon gene
and E1A DNA/mRNA were detected at all time points (6, 12,
24, 48, 72 h).
Discussion
Adenovirus infection occurs in 7% of exacerbations, however
adenovirus 5 E1A was found in only two patients with
exacerbations of COPD. One of these two patients who had
detectable E1A and capsular gene, these were not present 3
months later, indicating an acute adenoviral infection. This
finding suggests that the initial positive E1A result was
related to an acute adenovirus infection, as the same
patient was negative for both on subsequent screening. Only
one patient in the stable COPD group had detectable E1A
and also tested positive for the adenovirus hexon gene.
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Table 1 Patient demographics.
Measurement Patient group
Exacerbated COPD Stable COPD (reviewed) Stable COPD
No. of patients 136 33 35
Sex (M/F) 64/72 14/19 16/19
Age 7079.4 6978.4 6479.7
FEV1-litres (% Pred.) 0.8470.47 (39720) 0.9070.4 (48723) 0.9870.5 (48722)
Smoking (Pk/Yr) 48.0739.2 45.9729.7 38.7721.8
Table 2 Cell count and PCR assay results.
Measurement Patient group
Exacerbated COPD Stable COPD (reviewed) Stable COPD
No. of patients 136 33 35
Adenovirus 10/136 2/33 2/35
Hexon gene (%) 7 6 6
E1A DNA 2/136 1/33 0/35
Positive (%) 1.5 3 0
E1A DNA (1) 341,500,y 3003 0
Copy no./cellz (2) 1,597,413
E1A mRNA 2/136 1/33 0/35
Positive (%) 1.5 3 0
E1A mRNA (1) 70,100,y 1257 0
Copy no./cellz (2) 130
Epithelial cell count ( 104/mm3) 1.0 (0.13–3.81) 2.63 (0.82–8.0) 2.69 (0.91–5.84)
GAPDH 6755 1548 82
Copy no./cell (1879–40,370) (337–3933) (24–275)
Positive on testing for the adenovirus hexon gene.
yNegative for both Adenovirus hexon gene and E1A (DNA & mRNA) on repeat testing 3 months later.
zCorrected to epithelial cell count. (1) and (2) identify two individual patients.
T.E. McManus et al.2088These findings suggest that in two cases the initial positive
E1A result was related to an acute adenoviral infection. In
one patient in the exacerbation group in whom E1A DNA and
mRNA were detected in the absence of the hexon gene is a
potential representative of a patient with a latent infection.
The detection of latent adenoviral infection is lower than
has previously been reported,5 potential reasons are
discussed later in this paper. The detection of capsular gene
in the absence of adenovirus 5 E1A occurs in infection with
adenovirus which is not adenovirus 5. There are over 50
different serotypes of adenovirus which have been isolated
and characterized into 6 subgroups (A–F). Ten patients in the
exacerbated group and a total of four in the stable group
tested positive for the adenovirus hexon gene. As detailed
above only two of these patients also had detectable E1A
implying that in the remainder of cases the infection was
with an adenovirus other than adenovirus 5. The detection
rate of adenovirus in exacerbations of COPD is higher in this
study than has been previously reported.9,10 This may be in
part due to increased sensitivity of using a nested PCR
technique or alternatively a coincidental clustering of cases
during the recruitment phase of this study. This studyincluded two adenovirus E1A assays which were directed at
detecting adenovirus E1A DNA and a separate assay to
measure adenovirus E1A mRNA. Thus each specimen was
tested twice for different regions of the E1A sequence.
This study differed from others in that we examined
respiratory secretions whereas previous investigators looked
at lung tissue.5 However, the hypothesis that has been put
forward is that E1A is located in the epithelial cell.5 The
airway is lined extensively with epithelial cells which are
shed in sputum. In this study there were a median of 1 104
or more epithelial cells per ml of specimen and we utilized
assays which had a detection limit of less than 5000 copies
per ml. Published experimental work used E1A positive
control specimens consisting of Graham 293 cells trans-
formed with 4–5 copies of the E1A region of adenovirus 5.5
There were similar levels of detection in positive control
samples as compared to clinical specimens. Thus E1A, if
present, would be detectable in the sputum specimens
analysed in this study using the real-time E1A assay
developed. However the above reasoning is based on E1A
residing predominantly within epithelial cells, if this were
incorrect lack of detection may be a reflection of the sample
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Adenovirus in COPD 2089used rather than actually reflecting a true negative result.
Also there is the possibility that viral latency or persistence
will not necessarily result in epithelial cell lysis, and thereby
lung epithelial cells harboring viral nucleic acid might not be
shed into sputum.
As a positive control study we infected primary bronchial
epithelial cells with adenovirus 5. All cultures became
infected and demonstrated shedding of higher copy numbers
of viruses than were contained in the initial inoculum (data
not shown). In each case high copy numbers of E1A were
detectable, confirming its role in adenovirus infection. E1A
was found in all positive control samples of adenovirus
infected cultured epithelial cells which were sampled at
different time points post inoculation (6, 12, 24, 48, 72 h),
illustrating that E1A was present over this range of sampling
time points. A strength of this study is that the controls were
not obtained from COPD patients and as such this factor
avoided any possibility of E1A infection of COPD control
samples acting as a confounding variable. A possible source
of error was that the relatively low numbers of epithelial
cells may result in E1A not being detected because it
thought to be present in these cells only. Although the
positive control specimens were not processed in the same
way as sputum specimens (i.e. using DTT) we still identified
the adenovirus hexon gene and E1A using PCR assays.
Sputum is known to contain PCR inhibitors, some authors
have suggested dilution of samples in an attempt to remove
these inhibitors, sample dilution was not performed in this
study and could be contested as a reason for reduced
detection of E1A.29 However GAPDH was detected in all
specimens and this result would preclude the possibility that
PCR inhibitors were the cause of the E1A negativity. The
findings of the present study should be confirmed with
analysis of lung tissue specimens in order to be directly
comparable with the initial findings in this area. The
possibility of persistent or latent viral infection playing a
role in the pathogenesis of COPD however remains an
attractive hypothesis. The predominance of a cytotoxic T
cell infiltrate response in the airway mucosa of COPD
patients would fit with a viral infection.Conclusions
In summary, this study has shown that adenovirus can infect
bronchial epithelial cells and that E1A is detectable in
experimental infection. Adenovirus was sometimes found in
COPD patients during exacerbation and when stable.
Adenovirus E1A DNA is rarely detected in sputum from
patients during exacerbations of COPD using a validated and
sensitive assay. Our data suggest that the persistence of
adenovirus 5 E1A in lung cells of sputum samples in patients
with COPD occurs infrequentlyAcknowledgements
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